Account wins from the 04/10/07 news brief

Share this article:
Wunderman has been selected to launch a consumer campaign for AstraZeneca's Faslodex, a medication that has been approved for use in postmenopausal women with hormone-receptor positive metastatic breast cancer that has progressed following therapy with a hormonal treatment like tamoxifen. Wunderman will handle DTC and DTP relationship marketing efforts aimed at raising awareness in late stage breast cancer patients. A print campaign is slated for summer 2007. In addition to Faslodex, Wunderman currently handles Arimidex and Casodex/Zoladex. All are part of AstraZeneca's oncology catalog.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.